Jaguar8 commented on a stock · Nov 2, 2024 05:31

NEWS

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from their two-part, open-label, multicenter study (NCT05027139) evaluating evorpacept, a CD47 blocker, combined with zanidatamab, a dual HER2-targeted bispecific antibody. Dr. Alberto J. Montero from University Hospitals Seidman Cancer Center will present the findings on December 12, 2024.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

8682 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

9342

Followers

Following

112K

Visitors